Objective: The truncated mitochondrial progesterone receptor (PR-M) is homologous to nuclear PRs with the exception of an amino terminus hydrophobic membrane localization sequence, which localizes PR-M to mitochondria. Given the matrilineal inheritance of both spontaneous preterm birth (SPTB) and the mitochondrial genome, we hypothesized that (a) PR-M is polymorphic and (b) PR-M localization sequence polymorphisms could result in variable progesteroneÀmitochondrial effects and variable responsiveness to progesterone prophylaxis. Methods: Secondary analysis of DNA from women enrolled in a multicenter, prospective, study of 17 alpha-hydroxyprogesterone caproate (17OHPC) versus placebo for the prevention of recurrent SPTB. DNA was extracted from stored saliva. Results: The PR-M localization sequence was sequenced on 344 patients. Sequences were compared with the previously published 48 base-pair sequence, and all were identical. Conclusions: We did not detect genetic variation in the mitochondrial localization sequence of the truncated PR-M in a group of women at high risk for SPTB.
Background
17 alpha-hydroxyprogesterone caproate (17OHPC) and other progesterone agents have been shown to reduce the recurrence of spontaneous preterm birth (SPTB) in high-risk women. [1] [2] [3] Over 12% of infants are delivered preterm, accounting for 70% of neonatal morbidity and mortality in the United States. 4 Some proportion of SPTB is inherited, as it frequently clusters in families, and maternal genotype appears to contribute to the risk of developing this complication. [5] [6] [7] [8] The mechanism by which progesterone reduces SPTB is unknown but may occur at the level of the progesterone receptor (PR).
The human PR (hPR) is a member of the steroid and thyroid receptor superfamily. The gene encoding this receptor is located on chromosome 11q22-23 and consists of 8 exons. Nuclear PRs exist primarily as 2 distinct isoforms, PR-A and PR-B, and have been found in gestational tissues including the amion and chorion. 9, 10 Progesterone binding induces conformational changes in the receptor, which lead to protein phosphorylation, dissociation from heat shock proteins, dimer formation, and nuclear transport of the active proteinÀprogesterone complex. These hormone-receptor complexes then bind to specific promoter regions of progesterone-responsive genes and act as transcription factors for these target genes, altering gene expression.
Progesterone is also responsible for rapid, nongenomic actions that cannot be explained through traditional steroidreceptor binding. Nongenomic actions of progesterone have been previously shown to increase intracellular calcium and regulate the relaxation of intestinal and uterine muscle. [12] [13] [14] Recently, a truncated progesterone receptor (mitochondrial progesterone receptor [PR-M]) has been described. 15 The complementary DNA (cDNA) for PR-M was originally cloned from human aortic and adipose cDNA libraries. Sequence analysis shows a unique 5 0 untranslated region, Kozack sequence, and coding sequence for the first 16 amino acids derived from intron sequence of the distal third intron of the PR gene. The remainder of the cDNA sequence is identical to exons 4 through 8 of the nuclear PR. The unique amino terminus results in a hydrophobic mitochondrial localization signal. 16 The PR-M receptor and protein has been found in high levels in the myometrium of pregnant women. Nongenomic actions of progesterone (including uterine muscle relaxation) may be initiated through this type of receptor. 17 We hypothesize that the hydrophobic localization sequence of PR-M is polymorphic. Given the matrilineal inheritance of PTB and the matrilineal inheritance of the mitochondrial genome, we further hypothesize that polymorphisms in the mitochondrial localization sequence of PR-M would correlate with the variable responsiveness to 17OHPC for the prevention of recurrent PTB.
Methods
This is a secondary analysis of women enrolled from September 1999 to February 2002 in a multicenter, prospective, double-blind, randomized controlled trial of 17OHPC versus placebo, conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) MaternalÀFetal Medicine Units (MFMU) Network. 1 The trial enrolled 463 women with a singleton gestation who had at least 1 prior SPTB, and randomized them to receive weekly injections of either 17OHPC (n ¼ 310) or placebo (n ¼ 153), beginning at 16 to 20 3/7 weeks gestation and continuing until 36 6/7 weeks gestation or delivery. The trial demonstrated a reduction in the rate of recurrent PTB from 54.9% in the placebo group to 36.3% in the treatment group (P < .001).
Institutional Review Board (IRB) approval and subject consent for the original study, as well as future analyses such as this study, were obtained at each of the 19 participating Network sites by trained research nurses. 1 As a part of the original trial protocol, maternal saliva samples were collected for future analyses. Saliva samples were originally labeled with unique, de-identified study codes and frozen at À20 C prior to DNA extraction in July and August 2008. Genomic DNA was extracted from samples using established methods (Puregene, Qiagen Systems, Valencia, California). DNA was then amplified using Invitrogen Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, California); amplicons were verified by electrophoresis, and excess primers and nucleotides were removed by the ExoSAP-IT reaction (Affymetrix, Cleveland, Ohio). The purified polymerase chain reaction (PCR) product was then sequenced for the hydrophobic localization sequence of PR-M using BigDye Terminator v1.1 (Applied Biosystems, Carlsbad, California) and custom primers, designed for the sequence of interest. The resultant DNA sequence was then compared to the previously published sequence. 15 
Results
DNA was successfully extracted from stored saliva samples of 367 patients with a history of at least 1 prior SPTB. DNA was unable to be extracted in sufficient quantity from 96 of the 463 patients in the original study. Gel electrophoresis of the PCR amplification product demonstrated isolation of the 48 basepair PR-M localization sequence (Figure 1 ). The localization sequence of PR-M was then successfully sequenced on 344 patients ( Figure 2 ). All 344 samples were found to have identical DNA sequences. This sequence was then compared to the previously published 48 base-pair sequence and was found to be identical. No genetic variation was observed in this signal sequence.
Discussion
The mitochondrial localization sequence of PR-M in 344 women with at least 1 prior SPTB is without variation and is genetically identical to the published sequence. Variation in responsiveness to 17OHPC for the prevention of recurrent PTB cannot be explained by examination of the PR-M mitochondrial localization sequence.
Numerous studies have demonstrated the actions of progesterone in the regulation of arterial and muscular relaxation throughout the body. Progesterone acts both through (1) traditional genomic pathways by binding a nuclear PR, forming a steroidÀreceptor complex, and altering gene transcription and (2) nongenomic pathways, which are less clearly understood but are responsible for the rapid actions of this hormone and may be modulated through membrane receptors.
The action of progesterone varies among tissues. For example, in the gallbladder, progesterone acts through nongenomicsignaling pathways including tyrosine kinase and cyclic adenosine monophosphate activity. 18 In vascular smooth muscle, PR variation has been noted, and theorized to be one potential cause of variable responsiveness and action in response to progesterone. 19 In uterine smooth muscle cells, progesterone decreases calcium influx and thus uterine contractility. 14, 20 The tissue specificity of progesterone action is likewise thought to mediated by tissue-specific PR expression and function. 21 Mitochondria are vital cell components involved with cellular energy and regulation of cellular apoptosis. Each mitochondrion has its own genome consisting of double-stranded mitochondrial DNA. Traditionally, mitochondrial action was thought to be regulated by second messengers. However, recent studies have confirmed the presence of steroid receptors (including glucocorticoid and estrogen receptors) in the mitochondrion. [22] [23] [24] [25] Neither PR isoform A nor B has been shown to localize to the mitochondria. 26 However, the PR-M receptor is a recently described receptor and has recently been shown to localize to the mitochondrial membrane. 16 Additionally, PR-M messenger RNA (mRNA) levels vary among different tissues in the body, with the highest levels found in muscular tissues including the heart and myometrium. 27 Despite localization of PR-M to the mitochondria, along with the known roles of mitochondria in the production and utilization of cellular energy and progesterone in muscle contractility, the PR-M hydrophobic mitochondrial localization sequence is not polymorphic and does not appear to contribute toward the variable responsiveness to progesterone for preterm birth prevention. Future studies should investigate other potential mechanisms of action of progesterone, which might include detailed sequencing of the known genomic PRs and correlating these findings with clinical outcomes. DNA extraction and analysis were conducted by Taueret Laboratories, Salt Lake City, UT. Taueret received a copy of the draft manuscript but had no input into the analysis of the data or the content of the manuscript.
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